Physician profile
Karla Ledoux
NPI 1760440341
$22,193.37
in general payments reported to CMS, 2019-2025
39 companies · $581 in 2025
The $581 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,836 · 2020: $3,854 · 2021: $6,694 · 2022: $698 · 2023: $785 · 2024: $746 · 2025: $581.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,112.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,111.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $18,726.30 | 2019-2025 | Austedo Xr, Austedo Xr |
| Emd Serono, INC. | $522.34 | 2023-2024 | Mavenclad, Mavenclad |
| Abbvie INC. | $508.67 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $286.87 | 2019-2025 | |
| Ucb, INC. | $277.87 | 2019-2025 | Rystiggo, Briviact |
| Lilly USA, LLC | $241.98 | 2021-2024 | Emgality, Reyvow, Amyvid |
| Livanova USA, INC. | $191.85 | 2019-2020 | |
| Pfizer INC. | $168.42 | 2023-2024 | |
| Allergan, INC. | $136.45 | 2019-2021 | |
| Amgen INC. | $124.97 | 2019 | |
| Sk Life Science, INC. | $87.45 | 2020-2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $86.10 | 2022 | |
| Argenx US, INC. | $59.92 | 2023-2025 | Vyvgart, Vyvgart Hytrulo |
| Neurocrine Biosciences, INC. | $58.88 | 2020-2022 | |
| Acadia Pharmaceuticals INC | $58.24 | 2020-2024 | Nuplazid |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karla Ledoux listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.